{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:39:36Z","timestamp":1792611576438,"version":"4.5.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>This study addressed the application of anidulafungin as a surrogate marker to predict the susceptibility of<jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>to caspofungin due to unacceptably high interlaboratory variation of caspofungin MIC values. CLSI reference broth microdilution methods and species-specific interpretive criteria were used to test 4,290 strains of<jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>(eight species), including 71 strains with documented<jats:italic>fks<\/jats:italic>mutations. Caspofungin MIC values were compared with those of anidulafungin to determine the percentage of categorical agreement (CA) and very major (VME), major (ME), and minor error rates, as well as the ability to detect<jats:italic>fks<\/jats:italic>mutants. For all 4,290 isolates the CA was 97.1% (0.2% VME and ME, 2.5% minor errors) using anidulafungin as the surrogate. Among the 62 isolates of<jats:named-content content-type=\"genus-species\">Candida albicans<\/jats:named-content>(4 isolates),<jats:named-content content-type=\"genus-species\">C. tropicalis<\/jats:named-content>(5 isolates),<jats:named-content content-type=\"genus-species\">C. krusei<\/jats:named-content>(4 isolates),<jats:named-content content-type=\"genus-species\">C. kefyr<\/jats:named-content>(2 isolates), and<jats:named-content content-type=\"genus-species\">C. glabrata<\/jats:named-content>(47 isolates) that were nonsusceptible (NS; either intermediate [I] or resistant [R]) to both caspofungin and anidulafungin, 52 (83.8%) contained a mutation in<jats:italic>fks1<\/jats:italic>or<jats:italic>fks2<\/jats:italic>. Eight mutants of<jats:named-content content-type=\"genus-species\">C. glabrata<\/jats:named-content>, two of<jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>, and one each of<jats:named-content content-type=\"genus-species\">C. tropicalis<\/jats:named-content>and<jats:named-content content-type=\"genus-species\">C. krusei<\/jats:named-content>were classified as susceptible (S) to both antifungal agents. The remaining 7 mutants (2<jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>and 5<jats:named-content content-type=\"genus-species\">C. glabrata<\/jats:named-content>) were susceptible to one of the agents and either intermediate or resistant to the other. Using the epidemiological cutoff value (ECV) of 0.12 \u03bcg\/ml for both caspofungin and anidulafungin to differentiate wild-type (WT) from non-WT strains of<jats:named-content content-type=\"genus-species\">C. glabrata<\/jats:named-content>, 42 of the 55 (76.4%)<jats:named-content content-type=\"genus-species\">C. glabrata<\/jats:named-content>mutants were non-WT and 8 of the 55 (14.5%) were WT for both agents (90.9% concordance). Anidulafungin can accurately serve as a surrogate marker to predict S and R of<jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>to caspofungin.<\/jats:p>","DOI":"10.1128\/jcm.00782-14","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T03:54:37Z","timestamp":1403322877000},"page":"3223-3229","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":51,"title":["Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria"],"prefix":"10.1128","volume":"52","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Diekema","sequence":"additional","affiliation":[{"name":"University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12039"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12041"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01256-09"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01373-10"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-12"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00443-09"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01590-09"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00308-13"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02481-13"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03880.x"},{"key":"e_1_3_2_13_2","volume-title":"M27-S4. Reference method for broth dilution antifungal susceptibility testing of yeasts: 4th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. M27-S4. Reference method for broth dilution antifungal susceptibility testing of yeasts: 4th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.01.004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02020-13"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01364-10"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01519-13"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01292-08"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00566-08"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1128\/9781555816728.ch115","volume-title":"Manual of clinical microbiology","author":"Howell SA","year":"2011","unstructured":"HowellSAHazenKC. 2011. Candida, Cryptococcus, and other yeasts of medical importance, p 1793\u20131821. In VersalovicJCarrollKCFunkeGJorgensenJHLandryMLWarnockDW (ed), Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.","edition":"10"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01711-09"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01674-13"},{"key":"e_1_3_2_23_2","volume-title":"M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00937-12"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-011-0054-x"},{"key":"e_1_3_2_26_2","volume-title":"M23-A3. Development of in vitro susceptibility testing criteria and quality control parameters","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. M23-A3. Development of in vitro susceptibility testing criteria and quality control parameters, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_27_2","first-page":"1379","volume-title":"Manual of clinical microbiology","author":"Ferraro MJ","year":"1995","unstructured":"FerraroMJJorgensenJH. 1995. Instrument-based antibacterial susceptibility testing, p 1379\u20131384. In MurrayPRBaronEJPfallerMATenoverFCYolkenRH (ed), Manual of clinical microbiology, 6th ed. ASM Press, Washington, DC.","edition":"6"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00229-2"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01551-06"},{"key":"e_1_3_2_30_2","volume-title":"M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06369-11"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05872-11"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit136"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1801.110556"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00136-13"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01686-10"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00998-09"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01102-12"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02390-09"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-06"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00782-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00782-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T13:30:56Z","timestamp":1689341456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00782-14"}},"subtitle":[],"editor":[{"given":"G. A.","family":"Land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1128\/JCM.00782-14"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00782-14","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"2014-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}